ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

DRCCA Bard Group Recommends No New Nationwide Screening Program Until More Research Is Done

November 5, 1982

NMP22 Assay More Effective Than Conventional Lab Test

January 27, 2006

National Coalition An Education Group, Chairman Says

May 3, 1985

Research vs. Delivery? Advisors Debate NCI Role In Review of Community Program.

November 21, 2008

Gregory Reaman Named Associate Director of FDA Office of Oncology Drug Products

June 3, 2011

In Brief: Jack McShulkis Dies Following Stroke; Congress Gives Final Approval to Appropriations Bill

October 28, 1983